The Boston-based biotech eschewed a traditional approach to vaccine development, instead pitching its use of mRNA technology to investors. That pitch paid off this year as the company stands to be one of the first to bring a Covid-19 vaccine to market. Hannah Kuchler, the FT’s US pharma and biotech correspondent, reports on Moderna’s race to find an immunisation for the novel coronavirus.
The FT is making key coronavirus coverage free to read for everyone. Go to ft.com/coronavirusfree to read the latest.
Read more here: Moderna’s Covid vaccine offers vindication of its unconventional approach
Review clips: Yahoo Finance, CNBC
See acast.com/privacy for privacy and opt-out information.
Introducing the FT Tech Tonic podcast. You can subscribe and listen to the rest of the series here.
From picking the best stocks to listening in on earnings calls, AI-powered systems are changing finance. But how big are the rewards, really? And what are the risks? In this episode Robin...
The City of London is home to some of the world’s biggest banks and busiest exchanges but the UK is just weeks away from leaving the EU single market and many questions about access to the bloc are still unresolved. Philip Stafford, editor of FT Trading Room, and Stephen Morris, the FT’s banking...
As protests following the killing of George Floyd in the US reverberated around the world this summer, Belgium, like many other countries, experienced its own reckoning: with a brutal colonial past, with the systemic racism that inhibits its black citizens today and with the question of what...